Hypersensitivity 2 and 3 Flashcards

1
Q

Define Type II hypersensitivity.

A

• In Type II hypersensitivity, IgG or IgM antibodies bind to antigenic determinants on the surface of host cells, leading to host cell destruction by activated complement and/or by cytolytic effector cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the cytolytic effector cells in Type II hypersensitivity?

A

• NK cells, neutrophils, eosinophils, monocytes, and macrophages.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the mechanism for activating the cytolytic effector cells in Type II hypersensitivity?

A

• Engagement of IgG Fc receptors and/or receptors for activated complement components (C3a, C3b, C5a) can lead to phagocytosis and/or release by the effector cell of
o superoxide anion (O2-)
o hydrogen peroxide (H2O2)
o tumor necrosis factor (TNF)
o or perforins (membrane perforating proteins similar to C9) that lyse the target cell.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are four examples of Type II hypersensitivity?

A
  • Transfusion Reactions
  • Hemolytic Disease of Newborn (HDN) aka erythroblastosis fetalis
  • Autoimmune Blood Dyscrasias
  • Hyperacute Graft Rejection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are Isohemagglutinins?

A

• Antibodies against isohaemagglutinins (wtf?) these are just the A or B proteins on blood vessels. They are called isoantigens because the are antigens from the same species of animal (as opposed to alloantigens from other species)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Explain ABO blood and how antibodies form.

A
  • However, newborns don’t have A B antigens.
  • It is still only a theory as to how we get the antigens.
  • The theory taught in this class is that we gain exposure to A-like and B-like antigens from bacteria and virus in our GI tract.
  • We produce antibodies to them. If we have A blood, we will eliminate the antibodies against A cells, but keep antibodies against B blood.
  • From there on, we are sensitive to a foreign blood type. (and vice versa if we have B blood).
  • This sensitivity occurs at 3-6 months of age, peaks at 5-10 years, and declines after that.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What happens if a person is infused with a mismatched blood type?

A

• If ABO mismatched red cells are infused, the serum antibodies will
o immediately agglutinate the red cells (possibly leading to life-threatening ischemia or embolism)
o or cause their destruction by complement mediated lysis
o or by phagocytosis by macrophages in the liver and spleen.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

There are more than 30 blood group systems that together comprise more than 200 allogeneic antigenic variants. What happens when we receive a mismatch from other blood group systems?

A
  • Non-ABO blood groups are mainly a problem when people have repeated transfusions.
  • Sensitization results from the first encounter with the foreign antigen.
  • A hemolytic reaction then occurs when erythrocytes bearing the same foreign antigen are subsequently administered.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Explain Hemolytic Disease of the Newborn aka erythroblastosis fetalis.

A
  • Hemolytic Disease of the Newborn (HDN): HDN or erythroblastosis fetalis is an example of active immunization by exposure to mismatched red blood cells.
  • In this case, a mother who is RH(-) (i.e., lacks the RhD antigen) is stimulated to make anti-D antibodies when Rh(+) red cells from the fetus enter her blood stream.
  • This happens during pregnancy, and especially at parturition.
  • The anti-D antibodies cause the mother no problem since her red cells are Rh-D negative.
  • However, in a subsequent pregnancy with an RhD(+) fetus, maternal IgG anti-D antibodies can cross the placenta and destroy the red cells of the fetus leading to serious illness and even death of the newborn.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Thought Question: Explain why HDN is less common when mother and fetus are mismatched for ABO as well as Rh antigens.

A
  • It seems paradoxical that greater antigenic mismatch should lead to a less serious immunological response.
  • However, when there is an ABO mismatch, the fetal red cells are rapidly destroyed by naturally occurring ABO antibodies.
  • This eliminates the source of D antigen which must be present persistently to induce active immunity and production of anti-D antibody.
  • This is the principle for Rhesus prophylaxis, in which anti-RhD antibodies are injected perinatally into Rh(-) mothers who have an Rh(+) fetus.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Explain Autoimmune Blood Dyscrasias.

A

• Dyscrasias is “an abnormal or disordered state of the body or of a bodily part. Stemming from the Greek root meaning bad mixture.”
• Under abnormal circumstances, autoantibodies may be produced that recognize one’s own red cells, platelets, lymphocytes or neutrophils.
• These antibody-tagged cells can then be eliminated through mechanisms of Type II hypersensitivity, leading respectively to
o Anemia
o Thrombocytopenia
o Lymphocytopenia
o Neutropenia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Explain how Type II reactions can arise through the production of antibodies to drugs or drug metabolite (e.g. penicillin) that can associate with host cell membrane proteins and in doing so becomes a hapten.

A
  • Drugs such as penicillin can attach to erythrocytes and cause IgG-mediated damage to erythrocytes.
  • The complement and Fc receptor-dependent clearance systems then eliminate any host cell to which the particular drug or metabolite has bound.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the Coombs’ test? How does it test for Type II hemolytic diseases?

A
  • Basically, in some blood diseases we produce antibodies to our own blood.
  • To test for this we do a Coombs’ Test.
  • We take a blood sample and “wash it.” Only the blood cells and the antibodies attached to the blood cells are left.
  • We test the blood with anti-human antibodies (like from a goat). If there are antibodies attached to the blood cells, the Coombs test is positive, and the sample coagulates.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the treatment for patients with autoimmune hemolytic anemia, thrombocytopenia, or similar diseases?

A

• In patients with these disorders, a splenectomy may be performed to eliminate a major source of macrophages responsible for removing autoantibody-opsonized platelets or red blood cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Explain Hyperacute Graft Rejection

A
  • Hyperacute rejection occurs when a transplant recipient has been previously sensitized to antigenic determinants found in the engrafted tissue.
  • Preformed antibodies are thus present at the time of transplant, and cause Complement and/or Fc receptor-dependent destruction of the transplanted tissue.
  • The most serious reactions were previously due to ABO group antigens (which are expressed on kidney cells as well as erythrocytes), but ABO cross-matching has virtually eliminated this problem (making sure the donor ABO matches the recipient ABO).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Can Hyperacute rejection occur in any grafted tissue?

A

• Hyperacute rejection occurs only in grafts that are revascularized directly during transplantation, such as kidney grafts.
o When antibodies bind to the graft and activate complement, there is a dramatic influx of neutrophils followed by major damage to the glomerular capillaries, hemorrhage, platelet aggregation, and thrombus formation.
o The thrombi block the flow of blood to the tissues, which become anoxic and necrotic.

17
Q

What are TREATMENT Options for Type II Hypersensitivity Reactions?

A
  • If Drug induced, discontinue drug
  • Transfusion
  • Plasma exchange
  • Glucocorticoids
  • Cytotoxic Drugs (e.g. azathioprine) or anti-B cell antibody (e.g. Rituximab)
  • Splenectomy
  • Intravenous Immunoglobulins (IV Ig)
  • Drugs to stimulate Platelet or RBC productions
18
Q

. SUMMARY of Type II Hypersensitivity Reactions (contains some new info)

A

Antibodies to a variety of self antigens such as basement membranes of lung and kidney (Goodpasture’s syndrome), the acetylcholine receptor (Myasthenia gravis) and erythrocytes (hemolytic anemia) can result in ¬tissue damaging reactions. Drugs such as penicillin can attach to erythrocytes and cause IgG-mediated damage to erythrocytes.

19
Q

Define Type III Hypersensitivity.

A

• Type III hypersensitivity disease refers to the local, destructive inflammatory lesions that result from tissue deposition of complexes containing antigen, antibody and complement

20
Q

What is serum sickness?

A

• Serum sickness is a classical example of an immune complex disease that was common in the pre-antibiotic era, when serum from immunized animals (e.g. horses) was injected into humans to provide passive immunity to certain toxins or pathogens

21
Q

What are today’s major cause of Type III hypersensitivity?

A

• Today, allergic reactions to antibiotics are the major cause of the syndrome.

22
Q

Explain Figure 1: The time course of events associated with serum sickness following the injection of horse immunoglobulins (and keep on explaining Type III hypersensitivity and Serum sickness events)

A

• Antigen (horse immunoglobulin) concentrations in the serum reach a peak and fall quickly as antigen equilibrates between the serum and extravascular space.
• Antigen levels gradually decrease, reflecting the normal catabolic rate for immunoglobulin.
• Human antibodies specific to horse immunoglobulin are formed after 3 to 4 days, and ultimately (on about the 8th day after injection of the antigen) result in the formation of immune complexes large enough to be eliminated by macrophages.
• At this point, immune complexes are rapidly removed from the circulation.
• Concomitant with immune complex elimination, the following symptoms usually occur:
o fever, urticaria (hives), lymphadenitis (inflamed lymph nodes), arthritis (inflamed joints), glomerulonephritis (inflamed kidneys), carditis (inflammation of the heart), and neuritis (inflammation of nervous tissue).
• These symptoms are due to the local inflammatory response and mediator release initiated by immune-complex deposition in the involved tissues (eg., nervous tissue for neuritis; heart muscle for carditis, etc.)

Whoa. Then what happens?

  • Small, soluble immune complexes that escape phagocytosis may pass between vessel endothelial cells to deposit on the sub-endothelial basement membrane.
  • Neutrophils are attracted to the inflammatory site, probably due to complement activation (C5a generation), leukotriene B4 and IL-8 release.
  • If the immune complexes persist, they may induce the newly recruited neutrophils to release more leukotriene B4 and IL-8, as well as tissue-degrading lysosomal enzymes.

Up to here is the general mechanism for Type III Hypersensitivity Immune Complex Disease using the example of serum sickness.

In serum-sickness, the antigen (antibiotic or non-autologous serum) can be discontinued, and the inflammatory disease will subside.

23
Q

In contrast to serum-sickness, what happens with immune-complex diseases involve persistent antigens such as replicating viruses (vasculitis may be associated with chronic hepatitis B) or autoantigens (DNA, platelets, erythrocytes) involved in various autoimmune diseases?

A

• These antigens continue to provoke antibody production and immune-complex formation, causing persistent inflammation.
• The resultant diseases are often identified by the site at which they occur.
o These diseases include
• necrotising vasculitis (destructive inflammation of blood vessels)
• lymphadenitis (inflamed lymph nodes)
• periarteritis nodosa (inflamed nodal foci in small arteries)
• and arthritis.
• Systemic lupus erythematosus (SLE) is an immune complex disease which affects many organ systems, including skin, joints, arteries, muscle, pericardium and glomeruli. SLE is covered in more detail in the section on autoimmune disease.

24
Q

Define the following elements and how they are involved in Immune Complex Reactions. IgG or IgM antibody

A
  • Soluble complexes form in moderate Ag excess (3Ag/2Ab).
  • These complexes are an optimal size (19S or 106 daltons) to escape phagocytosis and may be retarded in capillaries, at bifurcations of arterioles, and on filtering membranes (eg., epithelial side of glomerular basement membrane).
  • The size of the complex is an important determinant of its potential to cause damage.
25
Q

Define the following elements and how they are involved in Immune Complex Reactions.Complement

A
  • is fixed by the complexes, generate C3a and C5a (anaphylatoxins)
  • which bind to C’ receptors on both mast cells and endothelial cells
  • resulting in blood vessels leakage and edema.
  • Ca and C5a is also chemotactic for neutrophils (along with IL-8 and LB4)
26
Q

IgG immune complexes

A
  • by cross-linking Fcγ receptors, induce neutrophils to release leukotriene B4 (chemotactic factor) and IL-8
  • induce macrophages, neutrophils and mast cells to release leukotrienes C4, D4 and E4 (slow reacting substance of anaphylaxis or SRS-A) and TNF (tumor necrosis factor).
  • Immune complexes trigger the release of lysosomal enzymes and superoxide anion from neutrophils, which result in damage to adjacent tissue.
27
Q

Define the following elements and how they are involved in Immune Complex Reactions. Leukotriene B4, SRS-A (i.e., leukotrienes C, D and E), prostaglandins and histamine

A

• cause increased vascular permeability which facilitates the localization of immune complexes on vessel basement membrane, a critical step in the development of vasculitis.

Secondary changes may occur, including formation of platelet and leukocyte thrombi (clumps), fibrin deposition, and vessel necrosis.

28
Q

What is the Arthus reaction?

A
  • is a prototype of the immune complex reaction when Ab is in gross excess.
  • Soluble Ag injected intradermally combines with Ab to form immune complexes that precipitate within venules at the Ag injection site in a manner similar to serum sickness, causing local erythema and edema.
  • The inflammatory reaction peaks within 3 to 8 hours.
29
Q

Define and explain the following Mechanisms of Immune Complex Clearance.

Mononuclear Phagocyte SystemMononuclear Phagocyte System

A
  • Mononuclear phagocytes (blood monocytes and tissue macrophages) specifically ingest immune complexes via their Fc and C3b receptors.
  • Tissue macrophages in the liver and spleen are especially important in this regard.
30
Q

C3b receptors on erythrocyte-complexes cleaned by liver Kupffer cells Mechanisms of Immune Complex Clearance.

A
  • After complement activation causes C3b deposition, the immune complex binds to type I complement receptors (CR1) on erythrocytes.
  • This sequesters the complex so it is unavailable for interaction with endothelial cells lining the blood vessels, and also shuttles the complexes to the liver and spleen for elimination.
  • Events in the liver are most clearly worked out.
  • As erythrocytes pass through the liver sinusoids, complexes—along with the complement receptor CR1—are stripped from the erythrocyte surface by macrophages (Kupffer Cells).
  • This is most efficient when an Fc receptor-mediated mechanism is activated on the Kupffer Cells.
31
Q

Mechanisms of Immune Complex Clearance. Complement

A

• While complement activation stimulates the inflammatory response associated with immune complex deposition, the alternate complement pathway is also able to mediate rapid and efficient dissolution of immune complexes.

32
Q

Mechanisms of Immune Complex Clearance.

A

• Polymorphonuclear neutrophils also have C3b and Fc receptors and probably play a role in immune-complex elimination.

33
Q

Mechanisms of Immune Complex Clearance. Other Mechanisms

A
  • Other cells containing Fc or C3 receptors include platelets, lymphocytes, mast cells, and renal and placental epithelia.
  • Platelets, for example, bind immune complexes that stimulate platelet aggregation and phagocytic removal by macrophages.
  • The other cells listed above may act in as yet unknown ways to help eliminate immune complexes.
34
Q

What are the variables that determine how complexes behave in different assay systems and which probably relate to their clinical importance?

A
  • isotype of the antibody
  • nature of the antigen
  • size of the complex
  • antigen-antibody ratio
  • ability to fix complement
  • concentration of the complex.
35
Q

Define the following most common and useful assays.

C1q binding

A
  • purified C1q will bind to immune complexes stoichiometrically.
  • Assays use either labelled C1q or solid-phase C1q which immobilizes immune complexes, followed by labelled rabbit anti-human immunoglobulin.
36
Q

Define the following most common and useful assays. CH50 (total hemolytic complement) of serum

A

• Since complement activation in vivo will result in decreased serum complement, measurement of serum complement is an indirect but useful measure of immune complex levels.

37
Q

Define the following most common and useful assays.

A

• both immunofluorescence and immuno-electron microscopy are used to identify tissue deposits of immune complexes

38
Q

What are TREATMENTS OF IMMUNE COMPLEX HYPERSENSITIVITY?

A
  • Withdrawal of culprit agent
  • Symptomatic treatment — Antihistamines, Non-steroidal anti-inflammatory agents and analgesics for low-grade fever and arthralgias.
  • Glucocorticoids — Higher fever (eg, temperature >38.5º C), more severe arthritis, arthralgias, more extensive rashes may be treated with short courses of glucocorticoids.